DK1216707T3 - Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet - Google Patents
Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidetInfo
- Publication number
- DK1216707T3 DK1216707T3 DK00403670T DK00403670T DK1216707T3 DK 1216707 T3 DK1216707 T3 DK 1216707T3 DK 00403670 T DK00403670 T DK 00403670T DK 00403670 T DK00403670 T DK 00403670T DK 1216707 T3 DK1216707 T3 DK 1216707T3
- Authority
- DK
- Denmark
- Prior art keywords
- binding sites
- specifically bind
- ligand molecules
- nep binding
- screening ligand
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00403670A EP1216707B1 (en) | 2000-12-22 | 2000-12-22 | Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide |
PCT/IB2001/002818 WO2002051434A2 (en) | 2000-12-22 | 2001-12-24 | Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1216707T3 true DK1216707T3 (da) | 2005-05-09 |
Family
ID=8174003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00403670T DK1216707T3 (da) | 2000-12-22 | 2000-12-22 | Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet |
Country Status (12)
Country | Link |
---|---|
US (4) | US7423020B2 (da) |
EP (3) | EP1216707B1 (da) |
JP (4) | JP4347566B2 (da) |
CN (2) | CN1217190C (da) |
AT (2) | ATE288763T1 (da) |
AU (2) | AU2002236100A1 (da) |
CA (2) | CA2431913A1 (da) |
DE (2) | DE60018085T2 (da) |
DK (1) | DK1216707T3 (da) |
ES (2) | ES2235806T3 (da) |
PT (1) | PT1216707E (da) |
WO (2) | WO2002051435A2 (da) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
CN1189211C (zh) | 1999-06-23 | 2005-02-16 | 巴斯德研究所 | 用于治疗人际关系异常和行为障碍的治疗方法和组合物 |
ATE288763T1 (de) * | 2000-12-22 | 2005-02-15 | Pasteur Institut | Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden |
PT1511472E (pt) * | 2002-05-29 | 2009-07-24 | Merck & Co Inc | Compostos úteis no tratamento de antrax e inibição do factor letal |
CN101787073B (zh) | 2003-01-28 | 2013-12-25 | 艾恩伍德医药品股份有限公司 | 治疗胃肠病的方法和组合物 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
PT1577320E (pt) | 2004-03-19 | 2012-10-30 | Pasteur Institut | Péptidos derivados da proteína bplp humana, polinucleótidos que codificam para os referidos péptidos e anticorpos dirigidos contra os referidos péptidos |
CN1950354A (zh) * | 2004-05-11 | 2007-04-18 | 默克公司 | N-磺酰化-氨基酸衍生物的制备方法 |
US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
CA3089569C (en) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
BRPI0906905B1 (pt) * | 2008-04-07 | 2022-09-13 | Institut Pasteur | Derivados de peptídeo, composição e uso de um derivado de peptídeo |
FR2931362B1 (fr) * | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
CA2930674A1 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CA2645452A1 (en) * | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
US20100221329A1 (en) | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
US8506544B2 (en) | 2010-06-21 | 2013-08-13 | The Procter & Gamble Company | Disposable absorbent pant with efficient design and convenient single-section side stretch panels |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2828346C (en) | 2011-03-01 | 2021-01-26 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US738778A (en) * | 1903-05-22 | 1903-09-15 | Cottrell C B & Sons Co | Sheet-delivery apparatus for printing and folding machinery. |
FI881869A (fi) * | 1987-04-25 | 1988-10-26 | Hoechst Ag | Enkastiner: nya glykopeptider med enkefalinashindrande verkan, foerfaranden foer deras framstaellning och deras anvaendning saosom farmaceutiska produkter. |
FR2637600B1 (fr) | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
US5550119A (en) * | 1995-03-02 | 1996-08-27 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives as ECE inhibitors |
US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
CN1189211C (zh) * | 1999-06-23 | 2005-02-16 | 巴斯德研究所 | 用于治疗人际关系异常和行为障碍的治疗方法和组合物 |
ATE288763T1 (de) * | 2000-12-22 | 2005-02-15 | Pasteur Institut | Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden |
-
2000
- 2000-12-22 AT AT00403670T patent/ATE288763T1/de active
- 2000-12-22 PT PT00403670T patent/PT1216707E/pt unknown
- 2000-12-22 EP EP00403670A patent/EP1216707B1/en not_active Expired - Lifetime
- 2000-12-22 DE DE60018085T patent/DE60018085T2/de not_active Expired - Lifetime
- 2000-12-22 ES ES00403670T patent/ES2235806T3/es not_active Expired - Lifetime
- 2000-12-22 DK DK00403670T patent/DK1216707T3/da active
-
2001
- 2001-12-24 US US10/451,073 patent/US7423020B2/en not_active Expired - Fee Related
- 2001-12-24 AT AT01985936T patent/ATE497390T1/de active
- 2001-12-24 CN CN018212654A patent/CN1217190C/zh not_active Expired - Fee Related
- 2001-12-24 AU AU2002236100A patent/AU2002236100A1/en not_active Abandoned
- 2001-12-24 JP JP2002552576A patent/JP4347566B2/ja not_active Expired - Fee Related
- 2001-12-24 ES ES01985936T patent/ES2363708T3/es not_active Expired - Lifetime
- 2001-12-24 WO PCT/IB2001/002819 patent/WO2002051435A2/en active Application Filing
- 2001-12-24 JP JP2002552577A patent/JP4409831B2/ja not_active Expired - Fee Related
- 2001-12-24 US US10/451,064 patent/US7153833B2/en not_active Expired - Lifetime
- 2001-12-24 DE DE60143990T patent/DE60143990D1/de not_active Expired - Lifetime
- 2001-12-24 CA CA002431913A patent/CA2431913A1/en not_active Abandoned
- 2001-12-24 AU AU2002234806A patent/AU2002234806A1/en not_active Abandoned
- 2001-12-24 EP EP01985459A patent/EP1343519A2/en not_active Withdrawn
- 2001-12-24 CA CA2431916A patent/CA2431916C/en not_active Expired - Lifetime
- 2001-12-24 EP EP01985936A patent/EP1343520B1/en not_active Expired - Lifetime
- 2001-12-24 WO PCT/IB2001/002818 patent/WO2002051434A2/en active Application Filing
- 2001-12-24 CN CNB018212646A patent/CN1229137C/zh not_active Expired - Fee Related
-
2006
- 2006-11-08 US US11/594,105 patent/US7625713B2/en not_active Expired - Fee Related
-
2008
- 2008-06-06 JP JP2008149611A patent/JP2009007352A/ja active Pending
- 2008-11-28 JP JP2008305315A patent/JP2009149633A/ja active Pending
-
2009
- 2009-10-16 US US12/580,701 patent/US20100041072A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1216707T3 (da) | Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet | |
DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
RS20060234A (en) | Fully human antibodies against human 4-1bb (cd137) | |
DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
WO2002002638A3 (en) | Methods for treating rheumatic diseases using a soluble ctla4 molecule | |
BR9508402A (pt) | Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união | |
FR12C0001I2 (fr) | Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b | |
CL2004000376A1 (es) | Compuestos derivados de fenil propil amidas n-(aminoiminometil o aminometil) susttiuidas; compuestos intermediarios; composicion farmaceutica; y su uso para tratar un efecto patologico de la trombina, como trastornos tromboticos venosos o arteriales. | |
DE69828614D1 (de) | Behandlung von Nierenfibrose durch Antikörper gegen integrin alpha-v-beta 6 | |
EA200801172A1 (ru) | Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения | |
MY130248A (en) | ANTIBODIES TO HUMAN IL-1ß | |
DE602004025101D1 (de) | Humane anti-humane cd3-bindungsmoleküle | |
DE60101669D1 (de) | Verwendung von botulinum-toxin zur behandlung von diabetes | |
DE60130256D1 (de) | Naphthalinderivate, die sich an den ep4?rezeptor binden | |
CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
DE60140069D1 (de) | Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür | |
EA200800642A1 (ru) | Специфичный к антигену са6 цитотоксический конъюгат и способы его применения | |
ATE292134T1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
NO20033949D0 (no) | Sammensetning og fremgangsmåte til å behandle neoplastiske sykdommer assosiert med forhöyede matriks metalloproteinaseaktiviteter ved åbenytte katechinforbindelser | |
DE50111331D1 (de) | Neue verwendung von proteinhydrolysaten | |
ATE378411T1 (de) | Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen | |
EE200200404A (et) | Kaltsiumdikarboksülaateetrid, nende valmistamismeetodid ja vaskulaarse haiguse ning suhkurtõve ravimine nendega | |
WO2004035606A3 (en) | Bace binding peptides and uses thereof | |
ATE492564T1 (de) | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum | |
DE60035787D1 (de) | Neuropeptid-Y1-Rezeptor-bindende Verbindungen zur Behandlung und Diagnose von Krebserkrankungen |